The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion

Kezhou Xia,Xinghan Huang,Zhun Wei,Zhou Wei,Weichun Guo

DOI: https://doi.org/10.21203/rs.3.rs-3519592/v1

2023-01-01

Abstract:Abstract Osteosarcoma is the most common aggressive bone cancer. In recent years, it has been found that many homeobox family genes are involved in the occurrence, development, and invasion of tumors. But what role does the HOX family play in osteosarcoma remain unclear. To investigate the role of the HOX family in osteosarcoma and to develop a risk prognostic model, we collected osteosarcoma patients’ information in The Cancer Genome Atlas (TCGA) cohort. We then used LASSO regression analysis and multivariate COX regression analysis to finalize four genes (HOXA1, HOXA5, HOXA6, HOXA13) to build a risk-prognostic model. Osteosarcoma patients were divided into high- and low-risk groups. The prognosis of the low-risk group was significantly better than that of the high-risk group, and the ROC curve could well simulate the survival time of patients. We then included the age and gender of the patients to construct a nomogram, which can better predict the overall survival time of the patients. Differences in gene function between the two risk groups were more concentrated in immune-related pathways, and GSEA analysis also suggested that the immune-enrichment pathway played an important role between the two groups. ssGSEA indicated that the immune cell content and immune function in the high-risk group were relatively deficient. Finally, HOXA1 was selected for in vitro and in vivo experiments to verify. In summary, we constructed a risk prognosis model based on HOX family genes and identified HOXA1 for verification. This model has good accuracy and universality, which can improve the early diagnosis rate and predict the prognosis of osteosarcoma patients and can help clinicians make decisions and individualized treatment.